Independence Blue CrossCommercial · Administrative · Medical Policy · Transplant Surgery, Infectious Disease, PathologyLow impact
06.02.37a, Immune Cell Function Assay
Effective date
Not stated in the notice
Identified
Jun 25, 2026
Summary
This is a reissue with no substantive changes to Independence Blue Cross policy 06.02.37a. The policy maintains that immune cell function assays (CPT 86352) are considered experimental/investigational and are NOT covered for any indication, including transplant monitoring. The policy has been reissued annually since 2015 with no modifications to coverage status or guidelines.
Get alerts when payers change rules like this one
We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.
02This is a routine annual reissue with no changes to coverage policy.
03Billing team should verify that CPT 86352 continues to be flagged as non-covered/experimental in the billing system for all Independence Blue Cross commercial plans.
04Claims for immune cell function assays should continue to be denied as experimental/investigational per existing procedures.
05No workflow changes are necessary.
Codes mentioned
86352
Original notice
06.02.37a, Immune Cell Function Assay
medpolicy.ibx.com · Always check the source before changing claims.
Summaries are AI-assisted. Always confirm against the original payer notice.
What is PolicyChanges
One workspace for payer rules, prior auth, coding and compliance
Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.